This site is intended for healthcare professionals
Blue, green and purple abstract wave
Drug information

OTC
Read time: 2 mins
Last updated: 10 Feb 2018

Summary of product characteristics


1. Name of the medicinal product

First Aid Antiseptic Liquid or Antiseptic Liquid.


2. Qualitative and quantitative composition

Cetylpyridinium chloride 0.025% w/v


3. Pharmaceutical form

Liquid


4.1. Therapeutic indications

For the treatment of cuts, grazes, insect bites and stings, boils, spots and pimples. For the relief of symptoms of sore throats including those associated with colds and flu. For the relief of mouth infections and daily oral hygiene. For the relief of minor burns and scalds and small areas of sunburn.


4.2. Posology and method of administration

Adults, children and the elderly:

Cuts, grazes, insect bites, stings, boils, spots and pimples

Apply undiluted to the affected area

Minor burns and scalds: small areas of sunburn:

Apply undiluted to the affected area

Adults and children over 6 years and the elderly

Mouth infections and oral hygiene

Thoroughly rinse the mouth with 15ml of undiluted liquid two or three times a day. Do not swallow.

Symptoms or sore throats those associated with colds and 'flu'

Gargle two or three times a day with 15ml of undiluted liquid. Do not swallow.


4.3. Contraindications

Hypersensitivity to any of the ingredients


4.4. Special warnings and precautions for use

Use for prolonged periods should be avoided.

Use over extensive areas should be avoided.


4.5. Interaction with other medicinal products and other forms of interaction

No clinically significant drug interactions.


4.6. Fertility, pregnancy and lactation

There are no data to confirm the safety of the product during pregnancy and lactation, but use as recommended would not be considered to constitute a hazard.


4.7. Effects on ability to drive and use machines

No adverse effects.


4.8. Undesirable effects

Occasional irritant or hypersensitivity reactions.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.


4.9. Overdose

In the case of ingestion, this may cause corrosive damage to the gastrointestinal tract, leading to pain, nausea, vomiting and diarrhoea. Signs of toxicity may also include euphoria, slurred speech, muscular incoordination, impairment of consciousness and coma. Treatment includes gastric aspiration and lavage. In children especially, overdosage could lead to hypoglycaemia, which should be treated with either oral or intravenous glucose.


5.1. Pharmacodynamic properties

Cetylpyridinium chloride is a cationic antiseptic with activity against both gram positive and gram negative organisms.


5.2. Pharmacokinetic properties

Not available.


5.3. Preclinical safety data

Not applicable.


6.1. List of excipients

Glycerol

Purified water

Alcohol 96%

Sodium citrate

Citric acid monohydrate

Methyl salicylate

Quinoline Yellow (E104)


6.2. Incompatibilities

Not applicable


6.3. Shelf life

36 months


6.4. Special precautions for storage

Protect from light. Store below 30°C.


6.5. Nature and contents of container

A clear polyethylene terephthalate (PET) 150ml bottle, with a polypropylene cap having a polyethylene liner or polypropylene cap with an expanded polyethylene liner or a thermoset cap with expanded polyethylene liner.

A pigmented polyethylene terephthalate (PET) 150ml bottle with a polypropylene cap having a polyethylene liner or polypropylene cap with an expanded polyethylene liner or a thermoset cap with expanded polyethylene liner.

An amber polyethylene terephthalate (PET) 150ml bottle with a polypropylene cap having a polyethylene liner or a polypropylene cap with an expanded polyethylene liner or a thermoset cap with expanded polyethylene liner.


6.6. Special precautions for disposal and other handling

Not applicable.


7. Marketing authorisation holder

The Boots Company PLC

1 Thane Road West

Nottingham, NG2 3AA


8. Marketing authorisation number(s)

PL 00014/0464


9. Date of first authorisation/renewal of the authorisation

23 January 1996


10. Date of revision of the text

5 February 2018

4.1 Therapeutic indications

For the treatment of cuts, grazes, insect bites and stings, boils, spots and pimples. For the relief of symptoms of sore throats including those associated with colds and flu. For the relief of mouth infections and daily oral hygiene. For the relief of minor burns and scalds and small areas of sunburn.

4.2 Posology and method of administration

Adults, children and the elderly:

Cuts, grazes, insect bites, stings, boils, spots and pimples

Apply undiluted to the affected area

Minor burns and scalds: small areas of sunburn:

Apply undiluted to the affected area

Adults and children over 6 years and the elderly

Mouth infections and oral hygiene

Thoroughly rinse the mouth with 15ml of undiluted liquid two or three times a day. Do not swallow.

Symptoms or sore throats those associated with colds and 'flu'

Gargle two or three times a day with 15ml of undiluted liquid. Do not swallow.

4.3 Contraindications

Hypersensitivity to any of the ingredients

4.4 Special warnings and precautions for use

Use for prolonged periods should be avoided.

Use over extensive areas should be avoided.

4.5 Interaction with other medicinal products and other forms of interaction

No clinically significant drug interactions.

4.6 Fertility, pregnancy and lactation

There are no data to confirm the safety of the product during pregnancy and lactation, but use as recommended would not be considered to constitute a hazard.

4.7 Effects on ability to drive and use machines

No adverse effects.

4.8 Undesirable effects

Occasional irritant or hypersensitivity reactions.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

 

 

Disclaimer

The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.

Medthority will not be held liable for explicit or implicit errors, or missing data.

Reporting of suspected adverse reactions 

Drug Licencing

Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).